The FDA wants Bayesian trials, but who chooses the prior?

Abstract Earlier this year, new draft guidance from the US Food and Drug Administration encouraged the use of Bayesian methodology in clinical trials for new drugs. Lu (Maggie) Qian addresses some of the questions arising from this development

Authors

Institutions

Publication Details

Journal
Significance
Published
2026-06-08
DOI
https://doi.org/10.1093/jrssig/qmag038
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The FDA wants Bayesian trials, but who chooses the prior?

Lu Qian
Significance
Statistical Methods in Clinical Trials
article

The FDA wants Bayesian trials, but who chooses the prior?

Lu Qian
article en

Abstract

Abstract Earlier this year, new draft guidance from the US Food and Drug Administration encouraged the use of Bayesian methodology in clinical trials for new drugs. Lu (Maggie) Qian addresses some of the questions arising from this development

SignificanceVol. 23(4)
Statistical Service (CY)
Zero hunger
Openalex Percentile: Top 4%
Statistical Methods in Clinical Trials
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The FDA wants Bayesian trials, but who chooses the prior? — Lu Qian · Significance (2026) | TGRS Research Map | TGRS